The earnings call highlighted significant progress in clinical trials and promising data in the oncology segment, particularly with the advancement of VERSATILE-003 and positive results from VERSATILE-002. However, financial challenges were noted, including an increased net loss and a decreased cash balance. While the clinical outlook is promising, financial concerns remain a consideration.

Company Guidance

During the PDS Biotech Second Quarter 2025 Earnings Conference Call, the management team provided guidance on their clinical programs and financial performance. They highlighted the advancement of the VERSATILE-003 Phase III clinical trial targeting HPV16-positive head and neck cancer, with a trial design that includes approximately 350 patients in a 2:1 randomization between the PDS0101-pembrolizumab combination arm and a pembrolizumab-only control arm. Emphasizing the significance of their approach, they reported that the median overall survival in the VERSATILE-002 trial remained steady at 30 months, and the lower limit of the 95% confidence interval increased to 23.9 months. Financially, PDS Biotech reported a net loss of approximately $9.4 million for Q2 2025, compared to $8.3 million in Q2 2024, with total operating expenses of $7.6 million and a cash balance of $31.9 million as of June 30, 2025. They also announced the expansion of a Phase II trial cohort for metastatic colorectal cancer following promising response rates.

Advancement of VERSATILE-003 Phase III Clinical Trial

PDS Biotech continued to advance its VERSATILE-003 Phase III clinical trial, focusing on HPV16-positive head and neck cancer, with a specific design targeting a significant unmet medical need.

Positive Data from VERSATILE-002 Trial

Updated data from the VERSATILE-002 trial demonstrated durable clinical benefit of PDS0101, with median overall survival steady at 30 months, and no new safety signals emerging.

Colorectal Cancer Cohort Expansion

The colorectal cancer cohort of the Phase II clinical trial with PDS01ADC met the criteria for expansion to Stage 2 following promising Stage 1 results, indicating potential for more effective treatments in this difficult-to-treat cancer.

Preclinical Efficacy of Novel Flu Vaccine

Preclinical efficacy and immune response data for a novel universal flu vaccine were featured at the American Association of Immunologists Immunology 2025 Annual Meeting.

Reduction in Operating Expenses

Total operating expenses decreased to $7.6 million compared to $8.7 million for the same period last year, primarily due to lower personnel costs and lower professional fees.

PDS Biotechnology (PDSB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PDSB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.20 / -	-0.29	―	―	―
Aug 13, 2025	2025 (Q2)	-0.23 / -0.21	-0.23	8.70% (+0.02)	―
May 14, 2025	2025 (Q1)	-0.25 / -0.21	-0.3	30.00% (+0.09)	―
Mar 27, 2025	2024 (Q4)	-0.28 / -0.21	-0.35	40.00% (+0.14)	―
Nov 14, 2024	2024 (Q3)	-0.30 / -0.29	-0.35	17.14% (+0.06)	―
Aug 13, 2024	2024 (Q2)	-0.33 / -0.23	-0.37	37.84% (+0.14)	―	―
May 15, 2024	2024 (Q1)	-0.37 / -0.30	-0.32	6.25% (+0.02)	―	―
Mar 27, 2024	2023 (Q4)	-0.44 / -0.35	-0.65	46.15% (+0.30)	―
Nov 14, 2023	2023 (Q3)	-0.45 / -0.35	-0.26	-34.62% (-0.09)	―
Aug 14, 2023	2023 (Q2)	-0.35 / -0.37	-0.2	-85.00% (-0.17)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PDSB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$1.23	$1.16	-5.69%
May 14, 2025	$1.27	$1.31	+3.15%
Mar 27, 2025	$1.24	$1.25	+0.81%
Nov 14, 2024	$2.76	$2.25	-18.48%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Pds Biotechnology (PDSB) report earnings?

Pds Biotechnology (PDSB) is schdueled to report earning on Nov 12, 2025, TBA (Confirmed).

What is Pds Biotechnology (PDSB) earnings time?

Pds Biotechnology (PDSB) earnings time is at Nov 12, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PDSB EPS forecast?

PDSB EPS forecast for the fiscal quarter 2025 (Q3) is -0.2.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing